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We present the case of a 69-year-old Caucasian man with a 5-year history of untreated chronic lym-
phocytic leukemia who presented with Merkel cell carcinoma on the right gluteal region. Six months
after surgical treatment of Merkel cell carcinoma, we detected massive lymphadenopathy in the right
retroperitoneum descending to the inguinum. A lymph node biopsy conﬁrmed Merkel cell carcinoma
relapse, and the patient was unsuccessfully treated with radiotherapy. As patients with chronic lym-
phocytic leukemia have a risk for developing a secondary malignancy, skin lesions need to be carefully
examined and new lymphadenopathy must be pathohistologically evaluated.
Copyright © 2015, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Chronic lymphocytic leukemia (CLL) is a B lymphocyte-derived
neoplasia and the most common adult leukemia, with an inci-
dence rate of three to ﬁve cases per 100,000.1 Usually, CLL has a
protracted course, but sometimes it is complicated by the occur-
rence of secondary malignancies.2 Merkel cell carcinoma (MCC) is a
rare, highly aggressive, primary cutaneous neuroendocrine malig-
nant tumor, which occurs with an estimated incidence rate of
0.18e0.41 cases per 100,000 persons and has a high mortality rate
of 33% at 3 years following diagnosis.3,4 Both malignancies tend to
occur in the elderly population, with a median age at diagnosis of
70 years for MCC and 72 years for CLL.5,6 MCC frequently occurs in
cancer survivors as well as in association with hematologic malig-
nancies, particularly B lymphoproliferative disorders.5 Indeed,
there is growing evidence that patients with CLL have a high risk for
developing MCC as a secondary malignancy.2,5,7e11y have no ﬁnancial or non-
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cal Association. Published by ElsevIn addition, both CLL and MCC can present with lymphade-
nopathy. MCC metastasizes principally via the lymphatics in a
stepwise fashion, with an initial involvement of the regional lymph
nodes and subsequent systemic spread.3 Lymphadenopathy
occurring in a patient with concomitant CLL and MCC presents a
clinical problem in terms of the differential diagnosis.
Here, we present a case of a patient, previously diagnosed with
both CLL and MCC, presenting with mass lymphadenopathy.
Case Report
A 69-year-old Caucasian man previously diagnosed with CLL was
referred to our clinic in April 2012 for a routine follow-up exami-
nation. At that time, he had CLL for 5 years (Rai 0) and did not
require any speciﬁc or supporting therapy. Physical examination
revealed an oval, red, ﬁrm, verrucous lesion (3  4 cm2) in the right
gluteal region, which the patient had noticed 4 months earlier and
which was growing rapidly. Other than this lesion, his physical
examinationwas unremarkable. With the exception of leukocytosis
(22.6  109/L) and mild creatinine elevation (139 mmol/L) due to
previously diagnosed chronic renal failure, his laboratory analyses
were normal. The skin tumor was completely excised (margins
were tumor free), and pathohistological analysis conﬁrmed MCC.
The tumor was located in the dermis and had inﬁltrated the sub-
cutaneous tissue. The tumor cells were monomorphic, with aier Taiwan LLC. All rights reserved.
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nant histological pattern was diffuse (Figure 1A). Immunohisto-
chemical analysis revealed that many of the tumor cells were
positive for synaptophysin (clone SP11; Thermo Lab Vision, Fre-
mont, California, USA) (Figure 1B), CK20 (clone Ks20.8; Thermo Lab
Vision) (Figure 1C), NSE (clone E27; Dako, Glostrup, Denmark)
(Figure 1D), chromogranin A (clone LK2H10; Thermo Lab Vision),
and AE1/AE3 (clone AE1/AE3; Thermo Lab Vision); there was focal
positivity for CD57 (clone NK1; Thermo Lab Vision) and EMA (focal)
(clone E29; Thermo Lab Vision). None of the tumor cells were
positive for LCA (clone PD7/26þ2B11; Thermo Lab Vision), CD10
(clone 56C6; Thermo Lab Vision), CD30 (clone Ber-H2; Thermo Lab
Vision), CD43 (clone DF-T1; Thermo Lab Vision), CD20 (clone L26;
Thermo Lab Vision), CD3 (clone SP7; Thermo Lab Vision), ALK
(clone SP8; Thermo Lab Vision), vimentin (clone V9; Thermo Lab
Vision), aktin (clone 1A4; Thermo Lab Vision), desmin (clone D33;
Thermo Lab Vision), S100 (polyclonal; Thermo Lab Vision), CD34
(clone QBEnd10; Thermo Lab Vision), and PSA (clone 35H9;
Novocastra, Nussloch, Germany). The proliferative fraction, as
detected by Ki-67 staining (clone SP6; Thermo Lab Vision), was
greater than 50% in some high power ﬁeld (HPF).
After surgery, adjuvant therapy was not advised. Six months
later, the patient presented with painless right inguinal lymph-
adenopathy and right leg edema. Computed tomography of
abdomen revealed a large (19  2.5  10.8 cm3) lobulated mass,
which enveloped the iliac blood vessels like a muff and descended
through the right inguinal region (Figure 2). His blood count was
stable, and there was no organomegaly. However, a clinical
dilemma with regard to the differential diagnosis of lymphade-
nopathy arose (CLL transformation vs. MCC metastasis). Therefore,
pathohistological analysis was required, and MCC inﬁltration of the
lymph nodes was conﬁrmed. As the tumor was inoperable, localFigure 1 Pathohistological and immunohistochemical features. (A) Low-power view showe
cells were monomorphic, with a minimal amount of cytoplasm and uniform nuclei. The pred
cells showed strong immunoreactivity for synaptophysin (original magniﬁcation, 100). (C
200). (D) Many tumor cells showed strong immunoreactivity for NSE (original magniﬁcatradiotherapy (total dose 36 Gy) was performed. However, a control
computed tomography scan showed local disease progression with
bladder inﬁltration. The patient was then treated with only palli-
ative symptomatic therapy.
Discussion
Patients with CLL have a risk of developing a second neoplasm,
particularly skin or lung cancer.2,12 The appearance of any suspi-
cious extranodal lesions and rapid lymph node enlargement
require urgent histological conﬁrmation in order to differentiate
between disease transformation (Richter syndrome) and secondary
malignancy. MCC is a relatively newly identiﬁed malignancy that
has occurred with increasing prevalence in the past decade.3,13 One
of the hallmarks of MCC is its tendency to occur in association with
other neoplasms, particularly B lymphoproliferative disor-
ders.4,5,7,9,14 A great number of case reports, as well as some larger
population studies, unequivocally showed that patients with CLL
were at increased risk for developing MCC, and vice versa.5,8,9,14
Despite extensive research, knowledge of the etiopathogenesis of
MCC is still limited. It has been postulated that exposure to ultra-
violet light and immunosuppression are risk factors for develop-
ment of MCC.3 Indeed, patients with chronic immunosuppression
are approximately 15 times more likely to develop MCC than age-
matched controls.15 On the other hand, immunosuppression is
one of thewell-known features of CLL. Although CLL is primarily a B
lymphocyte-derived neoplasia, it alters both cellular and humoral
immunity, including B- and T-lymphocytic, granulocytic, and
monocytic functions; natural killer cell and complement activity; as
well as cytokine balance.16 The recent discovery of the association
of Merkel cell polyomavirus (MCV) with MCC was a major contri-
bution to an improved understanding of this rare neoplasm'sd tumor growth in the dermis and inﬁltration of the subcutaneous tissue. The tumor
ominant histological patternwas diffuse (original magniﬁcation, 100). (B) Many tumor
) Strong staining for CK20 with inﬁltration of adipose tissue (original magniﬁcation,
ion, 100).
Figure 2 Abdominal computed tomography showed a lobulated mass, which envel-
oped the iliac blood vessels like a muff and descended through the right inguinal
region.
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approximately 70e80% of MCCs harbor MCV.8,17e19 More impor-
tantly, this virus could be the missing link between MCC and CLL.
Indeed, recent studies demonstrated the presence of MCV in
27e33% of patients with CLL.19,20 Additionally, immunosuppression
in CLL may favor the colonization of MCV, which can induce MCC
development.8,21
In our patient, MCC developed in the context of a 5-year history
of untreated CLL. This sequence of disease occurrence is common,
but there are also case reports describing the occurrence in reverse
order, with MCC developing before CLL.10,11 In addition, while there
is substantial variation in the timing of diagnosis of CLL and MCC, it
seems that MCC usually occurs within 3 years after CLL diagnosis.14
As in most other reported cases, our patient had Rai stage 0 CLL,
which was stable and required no speciﬁc or supporting therapy.10
MCC usually metastasizes to the lymph nodes, skin, and liver,
but all organ systems, including the central nervous system, may be
potentially affected.3 As MCC has a high probability of lymphatic
spread, it is extremely important to evaluate lymph nodes after
conﬁrmation of primary MCC. It is currently recommended to
perform sonography of the draining lymph nodes and abdomen, in
addition to performing chest radiography.3 Moreover, it is advised
to carry out a sentinel lymph node biopsy (SLNB) in all patients
with MCC regardless of whether they have lymphadenopathy or
not. These recommendations resulted from the apprehension of
many researchers who agree that there is no primary tumor size
that can reliably predict nodal involvement.3,13,22 This can be
particularly important for patients with concomitant CLL and MCC.
As an SLNB was not performed in our patient at the time of MCC
diagnosis, we cannot exclude the possibility of pre-existing MCC
metastases. If an SLNB had been done at the time of MCC conﬁr-
mation, radiotherapy of the regional lymph nodes might have
prolonged the course of the disease in our patient. In addition, an
SLNB would have potentially reduced the diagnostic dilemma
concerning the etiology of lymphadenopathy as well as hasten the
initiation of treatment.Several favorable prognostic factors for MCC have been identi-
ﬁed, including a primary tumor size of 2 cm or less, local disease,
female sex, and primary tumor localization on the upper limb.3 Of
these factors, our patient had only onedlocalized disease. Although
MCC in our patient at the time of diagnosis was notmacroscopically
disseminated, relapse occurred only 6 months after surgical treat-
ment. When MCC is a solitary neoplasm, it usually relapses within
the ﬁrst 2 years in up to 50% of patients.5 However, it has been
proved that patients with CLL who subsequently develop MCC have
substantially lower overall survival, which could be a consequence
of more aggressive forms of MCC that these patients are prone to
develop.14
As MCC is a radiosensitive tumor, it has been shown that adju-
vant radiotherapy delivered to the primary tumor site and regional
lymph nodes reduces recurrence, increases the 5-year survival rate,
and is the only signiﬁcant predictive factor for relapse-free sur-
vival.3,5,23 Although there are currently no prospective studies
addressing this issue, it is advised to consider radiation therapy as
the major prophylactic management after initial surgical treatment
of MCC.3,13 If our patient had received prophylactic radiotherapy,
the time to recurrence of his MCC might possibly have been
prolonged.
Eventually, our patient received radiotherapy (a total dose of
36 Gy) when his disease relapsed. His condition at that time did not
permit a higher radiation dose, but it should be noted that a pre-
vious study showed that doses of 55 Gy and higher provided the
best disease control when large tumor masses were present.24 This
could be another reason for treatment failure in our patient.
Conclusion
This report presents a case of concomitant CLL and MCC. Due to the
association between these malignancies, skin lesions in CLL pa-
tients should be examined and evaluated. As lymphadenopathy can
result from the spread of either neoplasm, lymphadenopathy seen
in patients with both CLL and MCC should be carefully evaluated.
We highlight the importance of lymph node biopsy and prompt
treatment of MCC, not only because MCC is a highly aggressive
neoplasm, but also because MCC on the background of CLL has a
worse prognosis.
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